Literature DB >> 22466555

Hydroxysafflor yellow A alleviates early inflammatory response of bleomycin-induced mice lung injury.

Yan Wu1, Lin Wang, Ming Jin, Bao-xia Zang.   

Abstract

Hydroxysafflor yellow A (HSYA) is an effective ingredient of Chinese herb Carthamus tinctorius L. The aim of this study was to evaluate the protective effect of HSYA on inflammatory phase of bleomycin-induced pulmonary injury in mice. Three doses of HSYA (26.7, 40, 60 mg/kg/d) were intraperitoneally injected to mice consecutively for 1 week after bleomycin administration. It was found that HSYA attenuated the loss in body weight, the increase of myeloperoxidase activity and pathologic changes of pulmonary inflammation caused by bleomycin. Treatment with HSYA also alleviated bleomycin-induced increase of mRNA level of tumor necrosis factor (TNF)-α, interleukin (IL)-1β and transforming growth factor (TGF)-β1 in lung homogenates. Moreover HSYA inhibited the increased activation of nuclear factor (NF)-κB and phosphorylation of p38 mitogen-activated protein kinases (MAPK) in lung tissue. These findings demonstrated that HSYA had protective effect on bleomycin-induced lung inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22466555     DOI: 10.1248/bpb.35.515

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  16 in total

1.  Hydroxysafflor Yellow A Attenuates Neuron Damage by Suppressing the Lipopolysaccharide-Induced TLR4 Pathway in Activated Microglial Cells.

Authors:  Yanni Lv; Yisong Qian; Aijun Ou-Yang; Longsheng Fu
Journal:  Cell Mol Neurobiol       Date:  2016-01-11       Impact factor: 5.046

2.  Protective effect of hydroxysafflor yellow A on bleomycin- induced pulmonary inflammation and fibrosis in rats.

Authors:  Ming Jin; Lin Wang; Yan Wu; Bao-Xia Zang; Li Tan
Journal:  Chin J Integr Med       Date:  2018-01-03       Impact factor: 1.978

3.  Inhibitory effect of hydroxysafflor yellow a on mouse skin photoaging induced by ultraviolet irradiation.

Authors:  Song-Zhi Kong; Xu-Guang Shi; Xue-Xuan Feng; Wen-Jie Li; Wei-Hai Liu; Zhu-Wen Chen; Jian-Hui Xie; Xiao-Ping Lai; Sai-Xia Zhang; Xiao-Jun Zhang; Zi-Ren Su
Journal:  Rejuvenation Res       Date:  2013-10       Impact factor: 4.663

4.  Protective effects of hydroxysafflor yellow A on β-amyloid-induced neurotoxicity in PC12 cells.

Authors:  Song-Zhi Kong; Yan-Fang Xian; Siu-Po Ip; Xiao-Ping Lai; Xu-Guang Shi; Zhi-Xiu Lin; Zi-Ren Su
Journal:  Neurochem Res       Date:  2013-02-19       Impact factor: 3.996

Review 5.  Natural product derived phytochemicals in managing acute lung injury by multiple mechanisms.

Authors:  Yu-Qiong He; Can-Can Zhou; Lu-Yao Yu; Liang Wang; Jiu-Ling Deng; Yu-Long Tao; Feng Zhang; Wan-Sheng Chen
Journal:  Pharmacol Res       Date:  2020-09-29       Impact factor: 7.658

6.  Chinese Herbal Preparation Xuebijing Potently Inhibits Inflammasome Activation in Hepatocytes and Ameliorates Mouse Liver Ischemia-Reperfusion Injury.

Authors:  Xiqiang Liu; Zhiqiu Hu; Bin Zhou; Xiang Li; Ran Tao
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

7.  Hydroxysafflor yellow A alleviates myocardial ischemia/reperfusion in hyperlipidemic animals through the suppression of TLR4 signaling.

Authors:  Dan Han; Jie Wei; Rui Zhang; Wenhuan Ma; Chen Shen; Yidong Feng; Nian Xia; Dan Xu; Dongcheng Cai; Yunman Li; Weirong Fang
Journal:  Sci Rep       Date:  2016-10-12       Impact factor: 4.379

8.  Hydroxysafflor yellow A improves established monocrotaline-induced pulmonary arterial hypertension in rats.

Authors:  Xiaotong Han; Yixiong Zhang; Zhou Zhou; Xingwen Zhang; Yanfei Long
Journal:  J Int Med Res       Date:  2016-04-08       Impact factor: 1.671

Review 9.  Alternative and Natural Therapies for Acute Lung Injury and Acute Respiratory Distress Syndrome.

Authors:  Vipul J Patel; Sreeja Biswas Roy; Hiren J Mehta; Myungsoo Joo; Ruxana T Sadikot
Journal:  Biomed Res Int       Date:  2018-05-16       Impact factor: 3.411

Review 10.  Hydroxysafflor Yellow A: A Promising Therapeutic Agent for a Broad Spectrum of Diseases.

Authors:  Hui Ao; Wuwen Feng; Cheng Peng
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-25       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.